Bristol Myers Squibb stock gains on positive Sotyktu data and raised analyst targets

Bristol Myers Squibb Company (ISIN US0897961004) stock is trading near USD 63.60 on the New York Stock Exchange as of September 16, 2026, following fresh Phase 3 data for its psoriasis drug Sotyktu and a higher analyst price target that underline confidence in its pipeline and earnings power.

Pipeline news and dividend support the shares

On September 17, 2026, Bristol Myers Squibb announced positive two-year Phase 3 results from the POETYK PsA-2 study of Sotyktu (deucravacitinib) in psoriatic arthritis, showing durable efficacy and a consistent safety profile over the treatment period, according to GuruFocus on September 17, 2026.

The same overview notes that Bristol Myers Squibb offers a dividend yield of 3.95 percent with a payout ratio of 39 percent and a three-year dividend growth rate of 4.4 percent, indicating that the current cash distributions are supported by earnings and cash flow, as highlighted by GuruFocus on September 17, 2026.

In addition, Bristol Myers Squibb declared a quarterly dividend of USD 0.63 per share, with analysts now assigning the stock an average rating of Moderate Buy and an average target price of USD 66.72 across the coverage universe, according to MarketBeat on September 16, 2026.

Earnings momentum from Q2 2026 results

The latest reported quarter underscores why the pipeline and dividend look sustainable: in the second quarter of 2026 Bristol Myers Squibb generated total revenue of USD 12,973 million, up 6 percent year over year, according to StockTitan in its summary of the company’s Form 8-K filing.

Within that total, the Growth Portfolio contributed USD 7,560 million in the quarter, which represents a 15 percent increase versus the prior-year period, while the Legacy Portfolio delivered USD 5,422 million, down 4 percent as generic erosion weighed on older brands, per StockTitan.

GAAP diluted earnings per share rose to USD 1.62 in Q2 2026 from USD 0.64 a year earlier, and non-GAAP diluted EPS increased to USD 2.04 from USD 1.46, showing a sharp improvement in profitability that outpaced revenue growth, according to StockTitan.

Key product Eliquis generated USD 4,481 million of revenue in the quarter, expanding 22 percent year over year and helping to offset declines in Revlimid and Pomalyst, as summarized by StockTitan.

On the back of these figures, Bristol Myers Squibb raised its 2026 non-GAAP revenue outlook to a range of USD 49.0 billion to USD 50.0 billion and increased its non-GAAP EPS guidance to USD 6.75 to USD 7.00 for the full year, signalling higher expectations versus earlier guidance and reflecting broad portfolio momentum and stronger Eliquis trends, according to StockTitan.

Analyst targets move higher on pipeline outlook

Analysts have responded to the combination of earnings traction and pipeline news with higher price targets: on September 16, 2026, Piper Sandler analyst David Amsellem reiterated an Overweight rating on Bristol Myers Squibb and raised his price target from USD 75.00 to USD 82.00, implying a 9.33 percent increase in his valuation of the stock, according to GuruFocus on September 16, 2026.

The same report notes that Piper Sandler’s new USD 82.00 target compares with a then current share price of USD 64.16, so the analyst saw more than USD 17.00 of upside per share at that point, as highlighted by GuruFocus.

A separate analyst round-up shows that Piper Sandler is not alone: UBS reiterated a Buy rating with an USD 80.00 target, Guggenheim maintained a Buy rating with an USD 75.00 target, and RBC Capital Markets kept a Sector Perform rating with a USD 64.00 price target, according to Investing.com on September 16, 2026.

In that overview, Bristol Myers Squibb shares were noted trading at USD 63.73 with a price-earnings ratio of 14.02, while 16 analysts had recently revised their earnings estimates upwards, providing a supportive backdrop for the raised targets, as reported by Investing.com.

Valuation and risk considerations for investors

Despite the earnings growth and analyst optimism, some valuation metrics suggest that Bristol Myers Squibb is trading above certain intrinsic value estimates: one GF Value analysis calculates an intrinsic value of USD 56.60 per share versus a current price of USD 63.60, meaning the stock is about 12.4 percent overvalued on that basis, according to GuruFocus.

However, the same analysis argues that the 3.95 percent dividend yield, modest payout ratio and ongoing dividend growth make the shares attractive for income-focused investors even at a premium to GF Value, as highlighted by GuruFocus.

On the risk side, the company continues to face patent and competitive pressures in oncology and immunology: for instance, Bristol Myers Squibb has moved to block a planned cancer biosimilar from Amgen for its blockbuster drug Opdivo by filing suit seeking to prevent manufacture while key patent rights remain in force, according to Law360 on September 16, 2026.

Investors therefore have to weigh the strong pipeline signals from Sotyktu and other growth drivers, the upgraded full-year guidance and supportive dividend against ongoing legal disputes and the possibility that competition and generic erosion continue to pressure parts of the Legacy Portfolio.

Stock level and trading context

Bristol Myers Squibb stock recently closed around USD 63.54 on the New York Stock Exchange on September 16, 2026, reflecting a modest 0.29 percent decline for that trading day compared with the prior close, while extended-hours trading showed a slight uptick to USD 63.68, according to a price snapshot cited by MarketBeat on September 17, 2026.

More news and analyses on Bristol Myers Squibb stock